East Ocyon Bio: Pioneering Off-the-Shelf Cancer Cell Therapies in 2026

30 SEC SUMMARY

East Ocyon Bio, an Indian biotech startup, is revolutionizing cancer treatment with its innovative off-the-shelf cell and gene therapies. Founded in 2022, the company has secured $4.2M in funding from Aeravti Ventures to develop scalable and affordable cancer therapies targeting solid tumors and hematological malignancies.

TABLE OF CONTENTS

1. About East Ocyon Bio
2. Business Model and Funding
3. The Science Behind Off-the-Shelf Cancer Therapies
4. Manufacturing Capabilities
5. Vision and Goals
6. Key Highlights
7. FAQs
8. Conclusion
9. Call-to-Action

About East Ocyon Bio

East Ocyon Bio is an Indian biotechnology company dedicated to developing next-generation cell and gene therapies for cancer, autoimmune disorders, and rare diseases. Founded in 2022, the company is headquartered in Gurugram, Haryana, India.

Business Model and Funding

East Ocyon Bio operates on a B2B and B2B2C business model, focusing on providing scalable and accessible cancer treatments. The company has raised $4.2M in seed funding from Aeravti Ventures in 2024, which will be used to advance its proprietary technology platforms and manufacturing capabilities.

The Science Behind Off-the-Shelf Cancer Therapies

East Ocyon Bio specializes in allogeneic, off-the-shelf cellular immunotherapies using immune cells such as Natural Killer (NK) cells and Gamma Delta T (γδ T) cells. Unlike conventional patient-specific (autologous) cell therapies, East Ocyon Bio’s approach aims to create therapies that can be mass-produced and made available to a broader patient population.

The company’s proprietary technology platforms are designed to enhance the ability of these immune cells to recognize and eliminate tumor cells. By leveraging CAR-NK and CAR-γδ T-cell therapies, East Ocyon Bio targets both solid tumors and hematological malignancies, offering a promising alternative to traditional cancer treatments.

Manufacturing Capabilities

East Ocyon Bio is building GMP-ready manufacturing capabilities to support the development and commercialization of its cellular therapies. The company’s vision is to develop curative allogeneic cell therapies in India and make them available to patients in India and global markets simultaneously.

The company’s research areas also include mRNA and gene therapy technologies, which further enhance its ability to innovate and scale its therapeutic pipeline. With a focus on affordability, quality, and timely access, East Ocyon Bio aims to contribute to the advancement of India's cell and gene therapy ecosystem.

Vision and Goals

East Ocyon Bio’s vision is to develop curative allogeneic cell therapies in India and make them available to patients in India and global markets simultaneously. The company’s goals include:

• Creating scalable and accessible treatment options for cancer patients.
• Ensuring affordability and timely access to innovative therapies.
• Advancing India's cell and gene therapy ecosystem through research and development.

Key Highlights

FAQs

FAQs

**Q1: Where is East Ocyon Bio headquartered? **A1: East Ocyon Bio is headquartered in Gurugram, Haryana, India.

**Q2: What is the business model of East Ocyon Bio? **A2: East Ocyon Bio operates on a B2B and B2B2C business model.

**Q3: What is the founding date of East Ocyon Bio? **A3: East Ocyon Bio was founded in 2022.

**Q4: How much funding has East Ocyon Bio raised till date? **A4: East Ocyon Bio has raised $4.2M in funding.

**Q5: When was the last funding raised by East Ocyon Bio? **A5: The last funding was raised in 2024 from Aeravti Ventures.

Conclusion

East Ocyon Bio is at the forefront of developing innovative off-the-shelf cancer cell therapies. With its cutting-edge technology and strategic vision, the company aims to revolutionize cancer treatment, making it more accessible and affordable for patients worldwide.

Call-to-Action

For more startup stories and insights, visit blogy.in.